Listen Now

On this episode of Psychedelic Insiders, Doug Drysdale, CEO of Cybin Inc. powers through a cold to share some insights on the present and future of psychedelic medicine. He talks to Microdose's Jason Najum about psychedelic drug development, mental health therapies involving psychedelics, and more.PSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company.LINKS: Video of interview: https://youtu.be/7AfG58q-KGwwww.cybin.comwww.microdose.buzzSubscribe today!on Apple Podcasts: https://podcasts.apple.com/us/podcast/psychedelic-insiders/id1531628901on Spotify: https://open.spotify.com/show/3Nyc58Ov7GYBeeLcWheBSxon Youtube: https://www.youtube.com/playlist?list=PLMj79P4l-kSl5YY6VA9mbkOxQPDrM5NE1

On this episode of Psychedelic Insiders, Jeeshan Chowdhury, Co-Founder & CEO of Journey CoLab opens up about his intentional path set for the company, using mescaline as medicine to combat endemic addictions like Alcohol Use Disorder. He talks to Jason Najum about drug development, psychedelic mental health care, and more.PSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company.LINKS: Video of interview: https://youtu.be/qq2wCyJ3aCcwww.journeycolab.comwww.microdose.buzzSubscribe today!on Apple Podcasts: https://podcasts.apple.com/us/podcast/psychedelic-insiders/id1531628901on Spotify: https://open.spotify.com/show/3Nyc58Ov7GYBeeLcWheBSxon Youtube: https://www.youtube.com/playlist?list=PLMj79P4l-kSl5YY6VA9mbkOxQPDrM5NE1

On this episode of Psychedelic Insiders, Najla Guthrie, CEO of KGK Science opens up about her 25 years experience in straightening out the wild field of natural medicines. She talks to Jason Najum about her business experience, how to go about drug development the right way, various regulatory bodies, and more.PSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company.LINKS: Video of interview: https://youtu.be/XJL1FKmi4JIwww.kgkscience.comwww.microdose.buzz

Janet talks about her mission to pursue breakthrough medicines via her company PurMinds Biopharma. She talks to Jason Najum about her business experience, ALS, data science, drug development, neuroscience, the FDA, and more.PSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company.LINKS: www.purminds.comwww.microdose.buzzSubscribe to the Playlist:https://www.youtube.com/playlist?list=PLMj79P4l-kSl5YY6VA9mbkOxQPDrM5NE1Hashtags: #PurMinds #FemaleCEO #BioPharma #JanetQi #MentalHealth #ALS #Psychedelics #Psychedelia #Health #Medicine #Healing #Pharmaceuticals #DrugDevelopment #ClinicalTrials

“Everyday is psychedelic”, that’s the motto of Psychedelic Water, the world’s first legal psychedelic beverage.Microdose writer Jason Najum sat down with Psychedelic Water CEO Pankaj Gojia to discuss the company's mission and product.PSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company.LINKS: VIDEO VERSION: https://youtu.be/kQA-Oemyy-Qwww.psychedelicwater.comwww.microdose.buzz

Robin Arnott has been studying ways of invoking psychedelic experiences through technology. Jason Najum goes deep into the nebulous realm of possible human experiences. Watch the live video interview at: https://youtu.be/p_coZ3pZ-wQPSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company.www.microdose.buzz

Matthew Johnson, graced by the psychedelic Gods with regulatory approval and grants from the US Federal government, has been studying psychedelics with fervour as they are his pharmacological passion. Jason Najum of Microdose Psychedelic Insights takes us on a wild ride of an interview that may or may not end in Jason's microdose turning him into a cat.PSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company.www.microdose.buzzMatthew JohnsonSusan Hill Ward Professor of Psychedelics and ConsciousnessJohns Hopkins University School of MedicineMatthew W. Johnson, Ph.D., is The Susan Hill Ward Endowed Professor of Psychedelics and Consciousness Research at Johns Hopkins University School of Medicine. Working with psychedelics since 2004, he is one of the world’s most widely published experts on psychedelics. He has published over 150 scientific papers, including psychedelic safety guidelines (2008) that helped to resurrect human psychedelic research, first research on psychedelic treatment of tobacco addiction (2014), and studies of psilocybin in cancer-related distress (2016) and depression (2020). His psilocybin review recommended Schedule IV upon potential medical approval (2018). Matt also conducts behavioral economic research on the psychology of addiction and sexual risk. He is a past President of the Psychopharmacology and Substance Abuse Division of the American Psychological Association, and current President of the International Society for Research on Psychedelics. In 2021 Matt received as principal investigator the first grant awarded by the US government in 50 years for a treatment trial of a classic psychedelic (psilocybin for smoking cessation). He has been interviewed by Anderson Cooper on 60 Minutes, the New York Times, the Washington Post, the Wall Street Journal, the BBC, CNN, Fox Business News, NPR, and in Michael Pollan’s book How to Change Your Mind. Twitter: @Drug_Researcher

In support of fellow advocates and entrepreneurs in the psychedelic medicine space, Mircrodose sat down with the team behind the "Psychedelic Frontiers Virtual Summit".The virtual conference is taking place this weekend and will feature interviews with over 40 leading experts in the field. The event is free to attend. Check it out at: www.psychedelicfrontiers.caPSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company.www.microdose.buzz

Microdose's Jason Najum sat down with Field Trip founder Ronan Levy to discuss the NASDAQ, new molecules, and how to bring magic and poetry to the business world.PSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company.Ronan Levy, Executive Chairman & Co-Founder, Field Trip HealthCo-founder of Field Trip Psychedelics, a partner at Grassfed Ventures, a venture capital and advisory firm focused on the cannabis and biotech industries and a director for Trait Biosciences Inc.www.microdose.buzz

PSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company.Nicholas Kadysh, PharmAla Biotech, Psyched WellnessNick Kadysh spent the majority of his career helping companies navigate complex regulatory risk in Healthcare. After a career in Government at the Federal and Provincial levels, he has served as Head of Corporate Affairs at JUUL Labs Canada, Government Affairs & Public Leader at GE Healthcare and Director of Public Affairs for Red Bull Canada. Nick is the Founder of PharmAla Biotech, dedicated to the manufacture of MDMA and MDXX class molecules for pharmaceutical research.www.microdose.buzzWatch this Podcast on Youtube: https://youtu.be/CgFqvnRLN6U

Episode 12 - August 12th 2020Brett J. Greene- Founder of Adelia TherapeuticsPresented by Paul Austin of The Third WaveAdelia TherapeuticsBrett has been an advocate for psychedelic research and education for over 20 years. He is the Research Administrator for the Center for Drug Discovery at Northeastern University, a position he has held for more than 10 years. He has co-managed over $80m in grant funding to support cannabinoid and serotonin research. He co-founded Psymposia in 2014, a prominent media and events company globally recognized for its social, political, and scientific coverage of the psychedelic movement, as well as having held numerous conferences and events around the globe.PSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company. 

Episode 11 - July 22nd 2020Ian McDonald - Founder of Bright Minds BiosciencesPresented by Paul Austin of The Third WaveBright Minds BiosciencesBright Minds is a biotechnology company with veteran drug hunters creating the next generation of psychedelics to treat mental health disorders. Ian is the Founder at Bright Minds Biosciences and is responsible for developing the overall strategic vision as well as adroitly assembling the intellectual and capital resources to bring scientific innovations to market. Prior to Bright Minds, he served on the management team at Avnel Gold – a TSX-listed gold mining, exploration, and development company with operations in Southwestern Mali in West Africa. In that capacity, McDonald developed and implemented the corporate strategy as it relates to M&A and capital markets resulting in a $160 million sale to Endeavor Mining within one year.PSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company. 

Episode 10 - July 15th 2020Natasha de Jong - Co-Founder and CEO at Earth ResonancePresented by Paul Austin of The Third WaveEarth ResonanceNatasha de Jong is the co-founder and CEO of Earth Resonance. With Earth Resonance, we are the no1. microdosing company for personal, spiritual and therapeutical transformation.Earth Resonance believes in medicine from the Earth, not from a lab. That is why we take an integrated approach. With our protocols, therapists and healing fungi, we raise your frequency naturally and offer life changing tools which supports this transformational process.Earth Resonance is located in the Netherlands and work together with industry leaders with more than 20 years of experience in the field of cultivating fresh psychedelic sclerotia. The company is proud to share with you their journey, testimonials of transformation and are looking forward to speak to you about the revolution of consciousness with psychedelics, botanicals and healing frequencies.PSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company. 

Episode 9 - July 8th 2020Ronan Levy - Executive Chairman at Field Trip HealthPresented by Alana Armstrong of Alan AldousField Trip HealthCo-founder of Field Trip Psychedelics, a partner at Grassfed Ventures, a venture capital and advisory firm focused on the cannabis and biotech industries and a director for Trait Biosciences Inc.PSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company. 

Episode 8 - July 1st 2020David Wood - Partner at Borden Ladner Gervais LLPPresented by Alana Armstrong of Alan AldousBorden Ladner Gervais LLPBorden Ladner Gervais LLP (BLG) delivers comprehensive legal solutions and client services for domestic and international clients — across more practice areas and industry sectors — than any other Canadian firm. BLG is the largest full-service law firm in Canada with over 700 lawyers, intellectual property agents and other professionals serving businesses and institutions across all legal needs.David holds a PhD in biochemistry and his formal graduate-level education in structural biochemistry, organic chemistry, physical chemistry, plant biochemistry, and natural products chemistry provides a strong technical background for advising clients in the Canadian cannabis industry in relation to both intellectual property and regulatory law.PSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company. 

Episode 7 - June 24th 2020Timothy Ko - CEO of Entheon BiomedicalPresented by Paul Austin of The Third Wave Entheon BiomedicalEntheon Biomedical is a biotechnology company committed to the development of safe & effective psychedelic medicines in order to provide patients with access to evidence-based treatments for addiction disorders. PSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company. 

Episode 6 - June 17th 2020Danny Motyka - CEO of PsygenPresented by Paul Austin of Third WavePsygenPsygen is a manufacturer of pharmaceutical-grade psychedelic drug products for clinical research and therapeutic applications. Danny Motyka has long been a proponent of psychedelic medicine. Personal experience with psilocybin and LSD helped him understand and manage major depression, and ultimately inspired him to dedicate his attention to psychedelic medicinal chemistry. After graduating from the University of Victoria with an honours degree in chemistry, he began his rise through management at Aurora Cannabis. His career with Aurora included multiple years as General Manager of a cannabis cultivation and processing facility, providing foundational experience with the intricacies of good manufacturing practices, and a strong knowledge of the Controlled Drugs and Substances Act and the associated regulations. PSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company. 

Episode 5 - June 10th 2020James Lanthier - CEO at Mindset PharmaPresented by Paul AustinMindset PharmaMindset is a psychedelic-based biopharmaceutical company that is focused on creating and developing a proprietary library of novel and patentable psychedelic therapeutics for the treatment of neurological and psychiatric disorders. James Lanthier is a seasoned technology executive with strong expertise in business building and corporate finance. Most recently, Mr. Lanthier co-founded Future Fertility, the leading developer of Artificial Intelligence applications for human infertility. Previously, was a founder and COO of Mood Media Corporation, which he grew along with the founding team to be the world's largest in-store media provider, serving over 300,000 retail and hospitality locations around the globe.PSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company. 

Episode 4 - June 3rd 2020Judy Blumstock - CEO at Diamond TherapeuticsPresented by Alana ArmstrongDIAMOND THERAPEUTICSDiamond Therapeutics is developing FDA-approved, psilocybin-based therapeutics that deliver patient benefits without undesired perceptual side effects.PSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company. 

Episode 3 - May 27th 2020Susan Chapelle - Co-CEO at HAVN LifePresented by Alana ArmstrongHAVN LIFEHAVN is creating standardized formulas using psychoactive compounds for scientific research and natural health care products for human performance.PSYCHEDELIC INSIDERSEach week, we'll be diving deep with psychedelic industry leaders into the startup scene, IPO tracks, the investment landscape, financing rounds, and the operational side of running a high-performance psychedelic company.